Beamtree Holdings Ltd (ASX: BMT) Share Price and News
Price
–
Movement
– ( )
(20 mins delayed)
52 Week Range
– - –
1 Year Return
Beamtree Holdings Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
–
Day Change
– ( )
52 Week Range
– - –
Yesterday's Close
–
Today's Open
–
Days Range
– - –
Volume
–
Avg. Volume (1 month)
–
Turnover
–
Beamtree Holdings Ltd (ASX: BMT)
Latest News

Ask a Fund Manager
2 small-cap ASX shares to handsomely reward patient investors

Technology Shares
Beamtree (ASX: BMT) share price rockets 21% on acquisition news
Frequently Asked Questions
-
No, Beamtree does not pay dividends at this time.
-
Beamtree Holdings Ltd listed on the ASX on 6 June 2019.
BMT ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|
About Beamtree Holdings Ltd
Beamtree Holdings Ltd (ASX: BMT) is a technology company involved in health data analytics. Its software incorporates artificial intelligence and machine learning to provide an integrated platform for information and knowledge management for health providers.
Beamtree's platform offers end-to-end support from data collection and classification through quality and performance benchmarking to clinical decision support at point of care.
The company says its products help healthcare providers to meet critical challenges in four key areas: rising demand, financial decision-making, quality of clinical outcomes, and patient experience.
BMT Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
13 Jun 2025 | $0.31 | $-0.01 | -3.13% | 137,639 | $0.33 | $0.33 | $0.31 |
12 Jun 2025 | $0.32 | $0.01 | 3.23% | 447,428 | $0.31 | $0.32 | $0.30 |
11 Jun 2025 | $0.31 | $0.01 | 3.33% | 448,729 | $0.31 | $0.32 | $0.29 |
10 Jun 2025 | $0.30 | $0.01 | 3.39% | 815,270 | $0.29 | $0.31 | $0.29 |
06 Jun 2025 | $0.30 | $-0.01 | -3.33% | 859,575 | $0.30 | $0.32 | $0.29 |
05 Jun 2025 | $0.30 | $0.01 | 3.39% | 95,400 | $0.30 | $0.30 | $0.29 |
04 Jun 2025 | $0.30 | $0.02 | 7.14% | 574,825 | $0.28 | $0.30 | $0.28 |
03 Jun 2025 | $0.28 | $0.00 | 0.00% | 551,649 | $0.29 | $0.30 | $0.28 |
02 Jun 2025 | $0.28 | $0.00 | 0.00% | 257,486 | $0.28 | $0.29 | $0.28 |
30 May 2025 | $0.29 | $0.01 | 3.64% | 61,128 | $0.28 | $0.29 | $0.28 |
29 May 2025 | $0.28 | $-0.01 | -3.51% | 51,165 | $0.29 | $0.29 | $0.28 |
28 May 2025 | $0.29 | $-0.01 | -3.45% | 205,279 | $0.29 | $0.29 | $0.28 |
27 May 2025 | $0.29 | $0.01 | 3.57% | 300,094 | $0.28 | $0.29 | $0.28 |
26 May 2025 | $0.28 | $0.00 | 0.00% | 213,966 | $0.29 | $0.29 | $0.27 |
23 May 2025 | $0.28 | $-0.01 | -3.45% | 5,960 | $0.29 | $0.29 | $0.28 |
22 May 2025 | $0.29 | $0.01 | 3.51% | 59,974 | $0.28 | $0.29 | $0.28 |
21 May 2025 | $0.29 | $0.01 | 3.64% | 93,802 | $0.27 | $0.29 | $0.27 |
20 May 2025 | $0.28 | $-0.01 | -3.51% | 793,416 | $0.29 | $0.30 | $0.27 |
19 May 2025 | $0.29 | $0.00 | 0.00% | 158,716 | $0.28 | $0.29 | $0.28 |
16 May 2025 | $0.28 | $0.02 | 7.69% | 150,792 | $0.28 | $0.28 | $0.28 |
15 May 2025 | $0.26 | $0.02 | 8.16% | 10,823 | $0.28 | $0.28 | $0.26 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
02 Jun 2025 | Brad Lancken | Transfer | 75,510 | $21,142 |
Off-market transfer. Assuming off market transfer of share
|
02 Jun 2025 | Brad Lancken | Exercise | 375,000 | $75,000 |
Exercise of options.
|
02 Jun 2025 | Brad Lancken | Transfer | 75,510 | $21,142 |
Off-market transfer. Assuming off market transfer of share
|
02 Jun 2025 | Brad Lancken | Issued | 375,000 | $75,000 |
Exercise of options.
|
30 Aug 2024 | Emma Gray | Issued | 75,510 | $15,857 |
Director remuneration.
|
30 Aug 2024 | Jim Birch | Issued | 4,081 | $857 |
Director remuneration.
|
30 Aug 2024 | Jim Birch | Issued | 71,429 | $15,000 |
Director remuneration.
|
30 Aug 2024 | Michael (Mike) Hill | Issued | 75,510 | $15,857 |
Director remuneration.
|
30 Aug 2024 | Brad Lancken | Issued | 75,510 | $15,857 |
Director remuneration.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Jim Birch | Non-Executive Director | Mar 2021 |
Mr Birch has more than 30 years of experience in implementing technological change in the healthcare industry, having previously served as Chair of the Australian Digital Health Agency, Deputy Chair of the Independent Hospital Pricing Authority, CEO of the SA Department of Health, and global healthcare leader for consulting firm EY. Jim is currently Chair of the Little Company of Mary Health Care (Calvary), and the Australian Red Cross Blood Service (now known as Lifeblood). Other current directorships include Women's and Children's Hospital Foundation. He is Chair Risk Committee.
|
Mr Michael (Mike) Hastings Hill | Non-Executive Director | Jun 2018 |
Formerly a Partner of Ernst & Young, has been involved in working with management teams and boards across a number of companies and industries for more than 20 years. He is the MD & CIO, Founder of the Bombora Special Investment Growth Fund. Prior to Bombora he was an Investment Partner with Ironbridge, a private equity investment fund which invested $1.5bn. Michael has served as Chairman of multiple ASX-listed companies over the past nine years. Other current directorships include Design Milk Co Limited (Non-Executive Chairman); Janison Education Group Limited (Non-Executive Chairman); Mad Paws Holdings Limited (Non-Executive Director); Gratifii Limited (Non-Executive Director). He is member of risk Committee.
|
Mr Brad Lancken | Non-Executive Director | Oct 2019 |
Mr Lancken is an experienced private and public company executive with over 20 years of experience and is a Managing Partner of Liverpool Partners with former roles at Archer Capital and Seven Group Holdings Limited. Bradley has global experience in the technology and SaaS sector including currently acting as a director of Seisma and SimplyAi (technology consulting businesses), Baby Village (ecommerce business) and former roles on the advisory board of China Media Capital Partners and iseekplant.com.au. He also has domestic health care experience, and is a director of Adora Fertility, Genea Fertility, and manages investment in Healthengine (a healthcare and GP marketplace technology company). Bradley serves the community as a Director of the NSW Institute of Sport.
|
Ms Emma Gray | Non-Executive DirectorNon-Executive Chairman | Nov 2022 |
Ms Gray is an experienced global business executive with over 20 years of experience in operations, strategy and digital transformation specifically in the retail, consumer and banking sectors. Emma was with ANZ Banking Group for 5 years, most recently as Group Executive, Data and Automation having previously been its Chief Data Officer. Prior to joining ANZ, Emma was a Group Executive with Woolworths, where she focused on Loyalty, Data and Strategy. Prior to executive life, Emma was a partner with Bain & Company, where she specialised in the retail and consumer segments, working across Australia, the United States and the United Kingdom for 15 years. Other current directorships: Sydney Dance Company; Bank of New Zealand. She is Member of Risk Committee.
|
Professor Andrew(Andy) Ian Hardy | Non-Executive Director | Mar 2025 |
Prof Hardy is Chief Executive Officer of University Hospitals Coventry and Warwickshire NHS Trust (UHCW), one of the tertiary acute hospital Trusts in England. He is also Deputy Chair of the National Improvement Board and on the board of several organisations, including the West Midlands Cancer Alliance and is a member of the Beamtree Global Impact Committee. In January 2016 Andy was appointed Professor of Industry at the University of Warwick and in 2022. In April 2023 he accepted the appointment of Professor for the Vice Chancellor Health Advisory Board, Coventry University. Andy has served as the President of Chartered Institute of Public Finance and Accountancy and the Healthcare Financial Management Association.
|
Mr Timothy Kelsey | Chief Executive Officer | Oct 2020 |
-
|
Ms Maria Clemente | Company Secretary | May 2024 |
-
|
Timothy Kelsey | Chief Executive Officer |
-
|
|
Mark McLellan | Chief Financial Officer and Chief Operations Officer |
-
|
|
Marek Stepniak | Chief Growth Officer |
-
|
|
Cheryl McCullagh | Chief Product Officer |
-
|
|
Maria Clemente | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Invia Custodian Pty Limited | 29,183,394 | 10.10% |
National Nominees Limited | 22,075,956 | 7.64% |
Mirrabooka Investments Limited | 18,837,828 | 6.52% |
Sandtree Pty Ltd | 18,035,378 | 6.24% |
Freestate Holdings Pty Ltd | 17,896,624 | 6.19% |
Amcil Limited | 10,045,097 | 3.48% |
HSBC Custody Nominees (Australia) Limited | 9,757,587 | 3.38% |
Shorebrook Pty Limited | 9,556,997 | 3.31% |
3rd Wave Investors Pty Ltd | 7,000,000 | 2.42% |
Netwealth Investments Limited | 6,714,086 | 2.32% |
Ozren Tosic | 3,273,150 | 1.13% |
Castlereagh Equity Pty Ltd | 3,250,000 | 1.12% |
KM Fitzpatrick & Associates Pty Ltd | 3,230,000 | 1.12% |
Dr Russell Kay Hancock | 2,500,000 | 0.87% |
Mr Christopher Bell | 2,499,000 | 0.86% |
Mrs Clare Mapledoram | 2,250,000 | 0.78% |
David Bambach | 2,073,545 | 0.72% |
Mary Ethna Black | 1,728,144 | 0.60% |
Brazil Farming Pty Ltd | 1,700,000 | 0.59% |
Smc Capital Pty Ltd | 1,550,000 | 0.54% |